Is there a causal role for homocysteine concentration in blood pressure? A Mendelian randomization study

American Journal of Clinical Nutrition

Volumn 103, Issue 1, 2016, Pages 39-49

  Borges, Maria C ^a   Hartwig, Fernando P ^a   Oliveira, Isabel O ^a   Horta, Bernardo L ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Blood pressure; Cohort studies; Homocysteine; Mendelian randomization; Molecular epidemiology

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; BIOLOGICAL MARKER;

ADULT; ALCOHOL CONSUMPTION; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; EDUCATIONAL STATUS; ELEVATED BLOOD PRESSURE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE MEASUREMENT; BRAZIL; GENETICS; HYPERTENSION;

ADULT; BIOMARKERS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BRAZIL; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84953898045     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.115.116038     Document Type: Article

References (57)

1. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20:295-300.
2. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
3. Eikelboom JW, Lonn E, Genest J Jr., Hankey G, Yusuf S. Homocyst(e) ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
4. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
5. Ganji V, Kafai MR. Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2003;77:826-33.
6. Kennedy BP, Farag NH, Ziegler MG, Mills PJ. Relationship of systolic blood pressure with plasma homocysteine: importance of smoking status. J Hypertens 2003;21:1307-12.
7. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002;156:1105-13.
8. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epi-demiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
9. Smith GD, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental dis-tinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352.
10. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23(R1):R89-98.
11. Clarke R, Bennett DA, Parish S, Verhoef P, Dotsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012;9:e1001177.
12. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, Breteler MM, Bautista LE, Sharma P, Whittaker JC, et al. Effect modi-fication by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378:584-94.
13. Martí-Carvajal AJ, Sola I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015;1:CD006612.
14. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:1622-31.
15. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al; International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and car-diovascular disease risk. Nature 2011;478:103-9.
16. van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH, Cotlarciuc I, Yuan X, Malarstig A, Bandinelli S, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr 2013; 98:668-76.
17. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, et al; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
18. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, et al. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. Diabetes 2010;59: 3229-39.
19. Erratum in: Diabetes 2011;60(3):1050-1.
20. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16.
21. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518: 197-206.
22. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015;518:187-96.
23. Victora CG, Barros FC. Cohort profile: the 1982 Pelotas (Brazil) birth cohort study. Int J Epidemiol 2006;35:237-42.
24. Horta BL, Gigante DP, Goncalves H, Dos Santos Motta J, Loret de Mola C, Oliveira IO, Barros FC, Victora CG. Cohort profile update: the 1982 Pelotas (Brazil) Birth Cohort Study. Int J Epidemiol 2015;44:441.
25. Babson AL, Olson DR, Palmieri T, Ross AF, Becker DM, Mulqueen PJ. The IMMULITE assay tube: a new approach to heterogeneous li-gand assay. Clin Chem 1991;37:1521-2.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
27. Kehdy FS, Gouveia MH, Machado M, Magalhaes WC, Horimoto AR, Horta BL, Moreira RG, Leal TP, Scliar MO, Soares-Souza GB, et al. Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA 2015;112: 8696-701.
28. Lohman T, Roche A, Martorell R. Anthropometric standardization reference manual. Champaign (IL): Human Kinetics Books; 1988.
29. Baum C, Schaffer M, Stillman S. Instrumental variables and GMM: estimation and testing. Stata J 2003;3:1-31.
30. Durbin J. Errors in variables. Rev Inst Int Stat 1954;22:23-32.
31. Wu D. Alternative tests of independence between stochastic regressors and disturbances. Econometrica 1973;41:733-50.
32. Hausman J. Specification tests in econometrics. Econometrica 1978;46: 1251-71.
33. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9.
34. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37:658-65.
35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-25.
36. StataCorp. Ivregress-wingle-equation instrumental-variables regression [cited 2015 Aug 2]. Available from: http://www.stata.com/manuals13/rivregress.pdf.
37. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygard O, Vollset SE. The Hordaland Homo-cysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 2006;136(6 Suppl): 1731S-40S.
38. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyper-homocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004;94:28-36.
39. Bagi Z, Ungvari Z, Szollar L, Koller A. Flow-induced constriction in arterioles of hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A(2) mediation. Arterioscler Thromb Vasc Biol 2001;21:233-7.
40. Welch GN, Upchurch GR Jr., Farivar RS, Pigazzi A, Vu K, Brecher P, Keaney JF Jr., Loscalzo J. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998; 110:22-31.
41. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 2002;252:497-503.
42. Charpiot P, Bescond A, Augier T, Chareyre C, Fraterno M, Rolland PH, Garcon D. Hyperhomocysteinemia induces elastolysis in minipig ar-teries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol 1998;17:559-74.
43. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyper-homocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002;22:772-80.
44. Williams C, Kingwell BA, Burke K, McPherson J, Dart AM. Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiff-ness independent of MTHFR genotype. Am J Clin Nutr 2005;82:26-31.
45. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001;21:2072-9.
46. McMahon JA, Skeaff CM, Williams SM, Green TJ. Lowering homo-cysteine with B vitamins has no effect on blood pressure in older adults. J Nutr 2007;137:1183-7.
47. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
48. Szabo de Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C, Hercberg S, Blacher J, Galan P. Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD. Br J Nutr 2012;107:921-7.
49. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008;123:15-33.
50. Bound J, Jaeger D, Baker R. Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. J Am Stat Assoc 1995;90: 443-50.
51. Stock J, Wright J, Yogo M. A survey of weak instruments and weak identification in generalized method of moments. J Bus Econ Stat 2002;20:518-29.
52. Staiger D, Stock J. Instrumental variables with weak instruments. Econometrica 1995;65:557-86.
53. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177-84.
54. Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2013;7:CD003833.
55. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-InterAct Consortium. Using published data in Mendelian ran-domization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30:543-52.
56. Food Fortification Initiative. Global progress [cited 2015 Jul 21]. Available from: http://www.ffinetwork.org/global-progress/.
57. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Meth-odological challenges in Mendelian randomization. Epidemiology 2014;25:427-35.